These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 19012393)

  • 21. Chemical library synthesis using convergent approaches.
    Beeler AB; Schaus SE; Porco JA
    Curr Opin Chem Biol; 2005 Jun; 9(3):277-84. PubMed ID: 15939329
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comprehensive survey of chemical libraries for drug discovery and chemical biology: 2006.
    Dolle RE; Le Bourdonnec B; Goodman AJ; Morales GA; Salvino JM; Zhang W
    J Comb Chem; 2007; 9(6):855-902. PubMed ID: 17877417
    [No Abstract]   [Full Text] [Related]  

  • 23. A versatile synthetic approach to peptidyl privileged structures using a "safety-catch" linker.
    Horton DA; Severinsen R; Kofod-Hansen M; Bourne GT; Smythe ML
    J Comb Chem; 2005; 7(3):421-35. PubMed ID: 15877471
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Strategy of molecular design of drugs: the unification of macro-properties and micro-structures of a molecule].
    Guo ZR
    Yao Xue Xue Bao; 2008 Mar; 43(3):227-33. PubMed ID: 18630256
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Voyages to the (un)known: adaptive design of bioactive compounds.
    Schneider G; Hartenfeller M; Reutlinger M; Tanrikulu Y; Proschak E; Schneider P
    Trends Biotechnol; 2009 Jan; 27(1):18-26. PubMed ID: 19004513
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Can we rationally design promiscuous drugs?
    Hopkins AL; Mason JS; Overington JP
    Curr Opin Struct Biol; 2006 Feb; 16(1):127-36. PubMed ID: 16442279
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The impact of combinatorial chemistry on drug discovery.
    Lee A; Breitenbucher JG
    Curr Opin Drug Discov Devel; 2003 Jul; 6(4):494-508. PubMed ID: 12951813
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Computational analysis of multi-target structure-activity relationships to derive preference orders for chemical modifications toward target selectivity.
    Wassermann AM; Peltason L; Bajorath J
    ChemMedChem; 2010 Jun; 5(6):847-58. PubMed ID: 20414918
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery and optimization of (R)-prolinol-derived agonists of the Growth Hormone Secretagogue receptor (GHSR).
    Zhai W; Flynn N; Longhi DA; Tino JA; Murphy BJ; Slusarchyk D; Gordon DA; Pendri A; Shi S; Stoffel R; Ma B; Sofia MJ; Gerritz SW
    Bioorg Med Chem Lett; 2008 Sep; 18(18):5083-6. PubMed ID: 18722770
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Automated medicinal chemistry.
    Koppitz M; Eis K
    Drug Discov Today; 2006 Jun; 11(11-12):561-8. PubMed ID: 16713909
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Integration of fragment screening and library design.
    Siegal G; Ab E; Schultz J
    Drug Discov Today; 2007 Dec; 12(23-24):1032-9. PubMed ID: 18061882
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular recognition: the fragment approach in lead generation.
    Fattori D
    Drug Discov Today; 2004 Mar; 9(5):229-38. PubMed ID: 14980541
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The design, synthesis and structure-activity relationships of 1-aryl-4-aminoalkylisoquinolines: a novel series of CRF-1 receptor antagonists.
    Yoon T; De Lombaert S; Brodbeck R; Gulianello M; Chandrasekhar J; Horvath RF; Ge P; Kershaw MT; Krause JE; Kehne J; Hoffman D; Doller D; Hodgetts KJ
    Bioorg Med Chem Lett; 2008 Feb; 18(3):891-6. PubMed ID: 18180159
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Finding multiactivity substructures by mining databases of drug-like compounds.
    Sheridan RP
    J Chem Inf Comput Sci; 2003; 43(3):1037-50. PubMed ID: 12767163
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CLEVER: pipeline for designing in silico chemical libraries.
    Song CM; Bernardo PH; Chai CL; Tong JC
    J Mol Graph Model; 2009 Jan; 27(5):578-83. PubMed ID: 18986817
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Parallel medicinal chemistry approaches to selective HDAC1/HDAC2 inhibitor (SHI-1:2) optimization.
    Kattar SD; Surdi LM; Zabierek A; Methot JL; Middleton RE; Hughes B; Szewczak AA; Dahlberg WK; Kral AM; Ozerova N; Fleming JC; Wang H; Secrist P; Harsch A; Hamill JE; Cruz JC; Kenific CM; Chenard M; Miller TA; Berk SC; Tempest P
    Bioorg Med Chem Lett; 2009 Feb; 19(4):1168-72. PubMed ID: 19138845
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 'Metabolite-likeness' as a criterion in the design and selection of pharmaceutical drug libraries.
    Dobson PD; Patel Y; Kell DB
    Drug Discov Today; 2009 Jan; 14(1-2):31-40. PubMed ID: 19049901
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modern natural products chemistry and drug discovery.
    Ojima I
    J Med Chem; 2008 May; 51(9):2587-8. PubMed ID: 18393400
    [No Abstract]   [Full Text] [Related]  

  • 39. Emerging chemical and biological approaches for the preparation of discovery libraries.
    Boldt GE; Dickerson TJ; Janda KD
    Drug Discov Today; 2006 Feb; 11(3-4):143-8. PubMed ID: 16533712
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Trifluoromethylpyrimidine-based inhibitors of proline-rich tyrosine kinase 2 (PYK2): structure-activity relationships and strategies for the elimination of reactive metabolite formation.
    Walker DP; Bi FC; Kalgutkar AS; Bauman JN; Zhao SX; Soglia JR; Aspnes GE; Kung DW; Klug-McLeod J; Zawistoski MP; McGlynn MA; Oliver R; Dunn M; Li JC; Richter DT; Cooper BA; Kath JC; Hulford CA; Autry CL; Luzzio MJ; Ung EJ; Roberts WG; Bonnette PC; Buckbinder L; Mistry A; Griffor MC; Han S; Guzman-Perez A
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6071-7. PubMed ID: 18951788
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.